Biopharmaceutical company developing antibody therapeutics for cancer and autoimmune diseases.
About
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics that selectively deplete pathogenic cells and disease-causing agents. Their proprietary Targeted Myeloid Engager and Phagocytosis Platform underpins their pipeline of first-in-class clinical and preclinical programs targeting oncology, autoimmune diseases, immunology, and neurology. Dren Bio aims to redefine treatment possibilities for patients with cancer and other serious diseases.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Dren Bio do?
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics that selectively deplete pathogenic cells and disease-causing agents. Their proprietary Targeted Myeloid Engager and Phagocytosis Platform underpins their pipeline of first-in-class clinical and preclinical programs targeting oncology, autoimmune diseases, immunology, and neurology. Dren Bio aims to redefine treatment possibilities for patients with cancer and other serious diseases.
How much funding has Dren Bio raised?
Dren Bio has raised a total of $156M in funding. The most recent round on record is Venture Round.
Where is Dren Bio headquartered?
Dren Bio is headquartered in San Carlos, United States.
When was Dren Bio founded?
Dren Bio was founded in 2019.
What industry does Dren Bio operate in?
Dren Bio operates in Biotech, Drug Discovery, Oncology, Autoimmune Diseases, Antibody Therapeutics, Immunology.